Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics drive U.S. drug sales growth

Executive Summary

Unbranded drug sales grew 22 percent in 2006, driving U.S. prescription drug sales up 8.3 percent to $274.9 billion during the year. According to IMS Health, which released annual sales figures March 8, strong generic sales were driven by Teva's simvastatin (Zocor), which generated $911 million in sales, and Apotex's generic clopidogrel (Plavix), which brought in $902 million. Medicare Part D was the other major sales growth driver, with prescriptions dispensed through the federal program accounting for 17 percent of retail scripts by the end of the year, IMS says. Biotech segment sales jumped 20 percent to $40.3 billion, driven by Amgen's Aranesp (up 42 percent to $3.9 billion), Enbrel (up 12 percent to $3.1 billion) and Neulasta (up 28 percent to $2.9 billion). Total U.S. prescription volume grew 4.6 percent in 2006 compared to 3.3 percent growth in 2005...

You may also be interested in...



Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs

Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.

MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’

The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel